If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mother Eddy deserves a place in the Trinity as much as any member of it. She has organized and made available a healing principle that for two thousand years has never been employed, except as the merest guesswork. She is the benefactor of the age." — Mark Twain, A Biography, by Albert B. Paine, Vol. III, p. 1271."
Roseanne Conner (née Harris) is played by Roseanne Barr. Roseanne, in a takeoff of her stand-up comedic and presumed real-life persona, is a bossy, loud, caustic, overweight, and dominant woman. She is also portrayed as smart, resourceful, and witty. She strives to control the lives of her sister, husband, children, co-workers, and friends. Despite a domineering nature, Roseanne is depicted as being a loving wife and mother who works hard and makes as much time for her husband and children as possible. She and her younger sister, Jackie, are the daughters of Beverly and Al Harris. Roseanne is married to Dan Conner and when the series begins they have three young children: Becky, Darlene, and David Jacob ("D.J."); a fourth child, Jerry Garcia, is born in the eighth season of the series. Roseanne and Dan mostly live paycheck-to-paycheck, raising a family amid the many hardships of poverty, obesity, and domestic troubles with love and humor. Roseanne works at the Wellman Plastics factory at the beginning of the show's run and quits after a conflict with her overbearing boss, Mr. Faber; she leads a walkout that includes Jackie and other co-workers. She is intermittently unemployed and holds jobs as a fast-food restaurant employee, a telemarketer, a bartender, and a shampooer/hair sweeper/receptionist at a beauty salon. Subsequently, she works for several years as a waitress in the luncheonette at Rodbell's department store located in the Lanford Mall (much to the chagrin of her daughters Becky and Darlene, who regularly hang out there).
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.
Sources: en.wikipedia.org
==== United Nations Climate Change Conference ==== On 1 November 2022, the COP27 host Egypt invited then President-elect Lula to visit the summit which raised hopes among climate activists and international organizations officials that Brazil will strengthen its environmental policies. Lula accepted the invitation and, while attending the COP27, promised to fight for a zero deforestation in the Amazon and other biomes. He also promised to have a United Nations Climate Change conference held in the Amazon. On 11 January 2023, Lula announced Brazil was making an official bid for the Brazilian city of Belém to host the COP 30. In May 2023, the UN announced that Belém had been chosen to host the summit, a first for a city in the Amazon region. During the COP28, Lula announced that Brazil would join the OPEC+ initiative, which focuses on integration and discussion between members of the group and other countries. He also announced a plan to recover degraded pasturelands, and to boost overall agriculture productivity through loans by Brazil's BNDES.
== Side effects == Cyclofenil is associated with a relatively high incidence of hepatotoxicity. Biochemical signs of undesirable liver changes have been observed in 35% or more of individuals and 1% of individuals experience overt hepatitis.
The Society recognizes achievements and promotes academic research through four annual awards. The Biemann Medal and the John B. Fenn Award for a Distinguished Contribution in Mass Spectrometry both are awarded in recognition of singular achievements or contributions in fundamental or applied mass spectrometry, with the Biemann Medal being focused on individuals who are early in their careers. The Ronald A. Hites Award is awarded for outstanding original research demonstrated in papers published in the Journal of the American Society for Mass Spectrometry. The Research Awards are given to young scientists in mass spectrometry, based on the evaluation of their proposed research. The Fellows of ASMS are awarded to individuals in recognition for their scientific contribution to mass spectrometry and for their contribution to the ASMS community. Journal of the American Society for Mass Spectrometry Measuring Mass: From Positive Rays to Proteins The past presidents of ASMS are:
There were many investigations, both theoretical and experimental, trying to determine the transition energy precisely and to specify other properties of the isomeric state of 229Th (such as its lifetime and magnetic moment), until the frequency was accurately measured in 2024. The first prototype nuclear clocks were announced in June 2026.
Sources: en.wikipedia.org
=== Georgia === Georgia first said that its military operation responded to Ossetian artillery attack on Georgian villages, and it intended to "restore constitutional order" in South Ossetia. Later, Georgia also said it aimed to resist a Russian invasion. President of Georgia Mikheil Saakashvili told journalists that around 23:00 on 7 August, Russian tanks had begun entering Georgia, causing the Georgians to respond with artillery weapons. Georgia made intercepted telephone calls public. The calls allegedly proved that entry of Georgian troops into Tskhinvali was preceded by movement of a Russian armoured regiment into South Ossetia nearly a day earlier.
Capstone Project MS degree: MS degree in pharmaceutical sciences with emphasis in cosmetic science (30 credit hours) Graduate Certificate (GC) in Cosmetic Science: 12 credit hours covering skin and hair science as well as formulation science MS and PhD degrees: intensive research-based MS and PhD degrees in pharmaceutical science with emphasis in cosmetic science (on-site at Cincinnati) Courses for non-matriculated students: Online courses are available to non-matriculated students who have not applied for acceptance into the GC or MS Programs (a maximum of six (6) semester credit hours may be transferred to either program upon matriculation). The graduate programs in cosmetic science grew from 17 students in 2013 to 96 students in 2017.
=== Synthetic dipeptides === Dipeptides are produced by coupling amino acids. The amino group on one amino acid is rendered non-nucleophilic (P in eq) and the carboxylic acid group in the second amino acid is deactivated as its methyl ester. The two modified amino acids are then combined in the presence of a coupling agent, which facilitates formation of the amide bond:
==== Germany ==== The drug is in Appendix III of the Narcotics Act (Betäubungsmittelgesetz or BtMG). The law allows only physicians, dentists, and veterinarians to prescribe oxycodone and the federal government to regulate the prescriptions (e.g., by requiring reporting).
=== New Zealand === On 12 March, the New Zealand Government released six days' worth of petroleum following a global directive by the International Energy Agency to release 400 million barrels of petrol in response to supply disruptions caused by the 2026 Iran war. On 24 March, the New Zealand Government announced that about 143,000 working families with children would receive a $50 tax credit to help with rising fuel costs from 7 April. Another 14,000 families were also expected to be eligible for a lower tax credit. On 27 March, the New Zealand Government released its four-level fuel alert level system in response to fuel shortages caused by the Iran conflict. That day the country was placed on the first phase, watchful, with the public advised to use fuel cautiously.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.